Skip to main content

Comparative efficacy and safety of mechanical circulatory support in ST-elevation myocardial infarction with cardiogenic shock: a network meta-analysis

In brief

Impella linked to 68% higher odds of short-term death than IABP

In a 22-study review of more than 360,000 patients with heart attack and cardiogenic shock, observational evidence linked Impella to higher odds of short-term death, bleeding, stroke and kidney injury than an intra-aortic balloon pump. The comparison may reflect which patients received each device, including salvage use, so the findings do not establish that Impella caused the worse outcomes.

Journal
Frontiers in cardiovascular medicine (Q1)
Published
28 October 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Boyu Guan, Xinsheng Li, Jiahua Zhang, Dongyuan Yu, Yujian Peng, Haichen Lv, et al.
PMID
43017029
DOI
10.3389/fcvm.2026.1782887

Why clinicians should know about it

Abstract

BACKGROUND: ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock carries high mortality, yet optimal treatment remains uncertain in this distinct patient population. The aim of this study is to systematically evaluate and compare the efficacy of mechanical circulatory support (MCS) devices, vasoactive agents, and inotropic agents in the management of critical adult patients with STEMI complicating cardiogenic shock. METHODS: A network meta-analysis (PROSPERO CRD420251002524) was conducted, with systematic searches of six databases (Embase, Web of Science, PubMed, and Cochrane, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform) from inception to March 2025 for randomized and observational studies. We also updated the search to September 2026 using the same search strategy. RESULTS: Data from 22 studies (pooled n = 360,235) revealed a predominantly male (65%), older adult population (mean age 67 years), US-based (97.9%) population with hypertension, hyperlipidemia, diabetes or heart failure. Compared with intra-aortic balloon pump (IABP), based on observational evidence, Impella was associated with a significantly higher risk of short-term mortality (odds ratio [OR] 1.68, 95% confidence interval [CI] 1.49-1.89), bleeding (OR 1.62, 95% CI 1.49-1.75), stroke (OR 2.67, 95% CI 1.01-7.03), AKI (OR 1.55, 95% CI 1.10-2.18), and AKI requiring dialysis (OR 1.67, 95% CI 1.50-1.87). Compared with control, Impella significantly increased the risk of stroke (OR 4.37, 95% CI 3.74-5.11). Randomized controlled trials (RCTs) have also supported an increased bleeding risk with Impella compared with IABP or standard care. CONCLUSION: For STEMI patients with cardiogenic shock, IABP may be considered as a mechanical support option when hemodynamically feasible. By contrast, Impella has been associated with an unfavorable risk-benefit profile in this population in observational studies, which may be heavily influenced by patient selection and salvage use. Therefore, its application warrants careful consideration if escalation is necessary. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251002524, PROSPERO CRD420251002524.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.